Thermal processing of a poorly water-soluble drug substance exhibiting a high melting point: The utility of KinetiSol® Dispersing

被引:57
作者
Hughey, Justin R. [1 ]
Keen, Justin M. [1 ]
Brough, Chris [2 ]
Saeger, Sophie [3 ]
McGinity, James W. [1 ]
机构
[1] Univ Texas Austin, Div Pharmaceut, Austin, TX 78712 USA
[2] DisperSol Technol LLC, Austin, TX 78759 USA
[3] Free Univ Berlin, D-14195 Berlin, Germany
关键词
Solid dispersion; High melting point drug substance; Thermally labile; Meloxicam; KinetiSol (R) Dispersing; Hot-melt extrusion; SOLID DISPERSIONS; EXTRUSION; DISSOLUTION; SOLUBILITY; POLYMERS; ITRACONAZOLE; ENHANCEMENT; EXCIPIENTS; MELOXICAM; FILMS;
D O I
10.1016/j.ijpharm.2011.08.007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Poorly water-soluble drug substances that exhibit high melting points are often difficult to successfully process by fusion-based techniques. The purpose of this study was to identify a suitable polymer system for meloxicam (MLX), a high melting point class II BCS compound, and investigate thermal processing techniques for the preparation of chemically stable single phase solid dispersions. Thermal and solution based screening techniques were utilized to screen hydrophilic polymers suitable for immediate release formulations. Results of the screening studies demonstrated that Soluplus (R) (SOL) provided the highest degree of miscibility and solubility enhancement. A hot-melt extrusion feasibility study demonstrated that high temperatures and extended residence times were required in order to render compositions amorphous, causing significant degradation of MIX. A design of experiments (DOE) was conducted on the KinetiSol (R) Dispersing (KSD) process to evaluate the effect of processing conditions on the chemical stability and amorphous character of MIX The study demonstrated that ejection temperature significantly impacted MLX stability. All samples prepared by KSD were substantially amorphous. Dissolution analysis of the KSD processed solid dispersions showed increased dissolution rates and extent of supersaturation over the marketed generic MIX tablets. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:222 / 230
页数:9
相关论文
共 38 条
[1]   Spray-dried amorphous solid dispersions of simvastatin, a low Tg drug:: In vitro and in vivo evaluations [J].
Ambike, AA ;
Mahadik, KR ;
Paradkar, A .
PHARMACEUTICAL RESEARCH, 2005, 22 (06) :990-998
[2]  
BASF, 2010, SOL TECHN INF, P3
[3]  
Bashiri-Shahroodi A, 2008, DRUG DEV IND PHARM, V34, P781, DOI [10.1080/03639040801925735, 10.1080/03639040801925735 ]
[4]   Melt extrusion: from process to drug delivery technology [J].
Breitenbach, J .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2002, 54 (02) :107-117
[5]   Characterization of physico-mechanical properties of indomethacin and polymers to assess their suitability for hot-melt extrusion processs as a means to manufacture solid dispersion/solution [J].
Chokshi, RJ ;
Sandhu, HK ;
Iyer, RM ;
Shah, NH ;
Malick, AW ;
Zia, H .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2005, 94 (11) :2463-2474
[6]  
Curatolo W., 2009, PHARM RES, V26
[7]  
DEHGHAN MHG, 2006, IRAN J PHARM RES, V4, P231
[8]   Production of advanced solid dispersions for enhanced bioavailability of itraconazole using KinetiSol® Dispersing [J].
DiNunzio, James C. ;
Hughey, Justin R. ;
Brough, Chris ;
Miller, Dave A. ;
Williams, Robert O., III ;
McGinity, James W. .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2010, 36 (09) :1064-1078
[9]   Applications of KinetiSol® Dispersing for the production of plasticizer free amorphous solid dispersions [J].
DiNunzio, James C. ;
Brough, Chris ;
Miller, Dave A. ;
Williams, Robert O., III ;
McGinity, James W. .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2010, 40 (03) :179-187
[10]   Fusion production of solid dispersions containing a heat-sensitive active ingredient by hot melt extrusion and Kinetisol® dispersing [J].
DiNunzio, James C. ;
Brough, Chris ;
Hughey, Justin R. ;
Miller, Dave A. ;
Williams, Robert O., III ;
McGinity, James W. .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2010, 74 (02) :340-351